J. Takeshita, MD, PhD, MSCE, Department of Dermatology, Department of Biostatistics, and Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
J. Chau, MCS, Patient Research Partner, Hong Kong Psoriatic Arthritis Association, Hong Kong, China.
J Rheumatol. 2022 Jun;49(6 Suppl 1):48-51. doi: 10.3899/jrheum.211330. Epub 2022 Mar 15.
There is increasing evidence of racial and ethnic disparities in the evaluation and treatment of people with psoriasis (PsO) and psoriatic arthritis, and inadequate racial/ethnic diversity in psoriatic disease (PsD) research. At the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2021 annual meeting, a program focusing on diversity, equity, and inclusion (DEI) was presented to highlight known health and healthcare disparities in PsD. There is limited understanding of the prevalence and severity of PsD and how it affects quality of life among racial/ethnic minorities with PsD. Educational gaps and lack of diversity in our dermatology workforce may be contributing to challenges in appropriately diagnosing and treating PsO in darker skin types. Racial/ethnic minorities are also inadequately represented in clinical research, including trial recruitment and participation, for PsD. A panel of patient research partners, researchers, and clinicians ended the session with a broad discussion on how GRAPPA can better ensure racial/ethnic DEI in their educational, research, and clinical missions.
越来越多的证据表明，在评估和治疗银屑病（PsO）和银屑病关节炎患者方面存在种族和民族差异，而在银屑病疾病（PsD）研究中，种族/民族多样性不足。在 2021 年 GRAPPA 年会上，提出了一个专注于多样性、公平性和包容性（DEI）的项目，以强调 PsD 中已知的健康和医疗保健差异。对于患有 PsD 的少数族裔而言，对 PsD 的患病率和严重程度以及它如何影响生活质量的了解有限。我们皮肤科劳动力中的教育差距和缺乏多样性可能是导致在深色皮肤类型中正确诊断和治疗 PsO 存在挑战的原因之一。在银屑病的临床研究中，包括试验招募和参与，少数族裔也代表性不足。一组患者研究合作伙伴、研究人员和临床医生结束了会议，就 GRAPPA 如何能够更好地确保其教育、研究和临床任务中的种族/民族 DEI 进行了广泛讨论。
